Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N4SU
|
|||
| Former ID |
DIB016301
|
|||
| Drug Name |
Pegorgotein
|
|||
| Synonyms |
Dismutec; Conjugated bSOD, Oxis; SOD, Sanofi; Superoxide dismutase, Sanofi; PEG-SOD, Oxis; PEG-SOD, Sanofi; PEG-bSOD, Oxis; PEG-bSOD, Sanofi; PEG-superoxide dismutase, Enzon Inc
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Head injury [ICD-11: NA00-NA0Z; ICD-10: S00.0S09; ICD-9: 800-879] | Terminated | [1] | |
| Company |
OXIS International Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H13NO4
|
|||
| Canonical SMILES |
COCCOC(=O)CCC(=O)N
|
|||
| InChI |
1S/C7H13NO4/c1-11-4-5-12-7(10)3-2-6(8)9/h2-5H2,1H3,(H2,8,9)
|
|||
| InChIKey |
VJDVWBDSMDTODO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 155773-57-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Superoxide dismutase Cu-Zn (SOD Cu-Zn) | Target Info | Modulator | [2] |
| BioCyc | Reactive oxygen species degradation | |||
| KEGG Pathway | Peroxisome | |||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Huntington's disease | ||||
| Prion diseases | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathwhiz Pathway | Degradation of Superoxides | |||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | |||
| FOXA1 transcription factor network | ||||
| Reactome | Platelet degranulation | |||
| Detoxification of Reactive Oxygen Species | ||||
| WikiPathways | Oxidative Stress | |||
| Copper homeostasis | ||||
| Detoxification of Reactive Oxygen Species | ||||
| Nifedipine Activity | ||||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Dopamine metabolism | ||||
| AGE/RAGE pathway | ||||
| Folate Metabolism | ||||
| Vitamin B12 Metabolism | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005631) | |||
| REF 2 | Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury. Adv Exp Med Biol. 1994;366:389-400. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.